The PRECISION Study

A Phase II study of 3 fractions of Prostate SBRT with RayPilot system & HypoCath image guidance for men with NCCN low or intermediate risk prostate cancer

The Precision study will investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to 3.  We will use a system called RayPilot HypoCath to continuously track the prostate position during the radiotherapy, so that the same treatment can be delivered over a 3-dose schedule. The study will look at whether the side effects are the same over the 3-dose schedule as the 5-dose schedule.

 

Chief Investigator: Prof Duncan McLaren

 

Number and location of participating sites (by region/ country): up to 10 UK sites

EudraCT number: N/A

ISRCTN number: N/A 

Clincaltrials.gov ref: NCT06117059

 

Funder: Jamie - King Urological Cancers Research Fund

 

Start and End date

Of grant award: from 01 May 2026

Of recruitment: from 01 Feb 2025

 

Current Status: Currently recruiting 

Trial Website: 

 

UK GDPR Privacy Statement: Within patient information sheet

 

Sponsor: ACCORD http://www.accord.ed.ac.uk/

Chief Investigator: Professor Duncan McLaren, Consultant Oncologist, Edinburgh Cancer Centre, Western General Hospital, Edinburgh, EH4 2LF   Email: Duncan.McLaren@ed.ac.uk

Trial Manager: Edinburgh Clinical Trials Unit, Usher Building, The University of Edinburgh, 5‒7 Little France Road, Edinburgh BioQuarter ‒ Gate 3 EDINBURGH EH16 4UX   Email:precision.study@ed.ac.uk

 

ECTU involvement: Trial Management / Statistics / Data Management

This article was published on